HCW Biologics Inc. Earnings Per Share Disclosure
10. Net Loss Per Share
The following table summarizes the computation of the basic and diluted net loss per share. The 977,000 of shares held in abeyance as of December 31, 2025 were included in the weighted-average common shares outstanding since all necessary conditions for issuance have been met.
|
|
Years Ended December 31, |
|
|||||
|
|
2024 |
|
|
2025 |
|
||
Numerator: |
|
|
|
|
|
|
||
Net loss |
|
$ |
(30,023,814 |
) |
|
$ |
(7,959,709 |
) |
Equity dividend to investor |
|
|
— |
|
|
|
(14,338,993 |
) |
Net loss attributable to Common Stockholders |
|
$ |
(30,023,814 |
) |
|
$ |
(22,298,702 |
) |
Denominator: |
|
|
|
|
|
|
||
Weighted-average common shares outstanding, basic and diluted |
|
|
969,825 |
|
|
|
2,097,701 |
|
Net loss per share, basic and diluted |
|
$ |
(30.96 |
) |
|
$ |
(10.63 |
) |
The following table summarizes the outstanding potentially dilutive securities that have been excluded in the calculation of diluted net loss per share because their inclusion would be anti-dilutive:
|
|
December 31, |
|
|||||
|
|
2024 |
|
|
2025 |
|
||
Common stock options |
|
|
44,601 |
|
|
|
44,193 |
|
Common stock warrants |
|
|
— |
|
|
|
3,146,950 |
|
Potentially dilutive securities |
|
|
44,601 |
|
|
|
3,191,143 |
|
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2025 | Mar 31, 2026 | Showing above |
| 2024 | Mar 28, 2025 | |
| 2023 | Apr 1, 2024 | |
| 2022 | Mar 28, 2023 | |
| 2021 | Mar 29, 2022 | |
About Earnings Per Share Disclosures
The earnings per share disclosure breaks down the calculation from net income to both basic and diluted EPS, revealing the full impact of a company's capital structure on per-share economics. The reconciliation between basic and diluted share counts exposes how many stock options, RSUs, convertible securities, and warrants are potentially dilutive to existing shareholders.
Key signals: a widening gap between basic and diluted shares indicates growing dilution from equity compensation or convertible instruments. Anti-dilutive securities excluded from the diluted calculation deserve attention — they represent latent dilution that will materialize if the stock price rises. Watch for the effect of share buybacks on per-share metrics: EPS growth driven primarily by repurchases rather than income growth signals weakening fundamentals. Compare year-over-year changes in the diluted share count against equity compensation expense to assess whether management is effectively managing dilution.